Key result
Targeted immune checkpoint inhibition yields >65 months of disease stability in MSI-high pulmonary artery sarcoma.
Why the study?
Does emergency surgery combined with biomarker-driven immune checkpoint inhibition improve survival and disease control in a patient with an MSI-high pulmonary artery sarcoma and Lynch syndrome?
Case Report (n=1)
Does emergency surgery combined with biomarker-driven immune checkpoint inhibition improve survival and disease control in a patient with an MSI-high pulmonary artery sarcoma and Lynch syndrome?
Emergency surgical resection enabled biomarker-driven immune checkpoint therapy, yielding exceptional long-term survival (>65 months) in a rare, aggressive pulmonary artery sarcoma associated with Lynch syndrome.
Answers are grounded in this paper and cite their sources.
Supports MSI testing and ICI in rare sarcomas; hypothesis-generating for Lynch-associated cases and requires prospective validation.
This report describes a rare case of a vascular-origin malignant tumor (intimal sarcoma or carcinosarcoma) extending from the right pulmonary hilum along the pulmonary artery in a 44-year-old man. The patient underwent right pneumonectomy under extracorporeal membrane oxygenation (ECMO) support and achieved long-term survival through molecularly guided immunotherapy. His medical history included two early-onset colorectal cancers and a family history of malignancy, suggesting an underlying hereditary cancer syndrome. The tumor exhibited microsatellite instability-high (MSI-high) status and a high tumor mutational burden (TMB-high) with low PD-L1 expression but responded favorably to immune checkpoint inhibitors, including ipilimumab plus nivolumab and pembrolizumab, achieving sustained disease stability for over 65 months. Comprehensive genomic profiling conducted as part of a branch study later in the disease course revealed a pathogenic germline MLH1 variant, confirming the diagnosis of Lynch syndrome. This case underscores the importance of surgery-enabled precision oncology in the management of rare and aggressive tumors.
No takes yet. Share an insight, caveat, or question.
Nigi et al. (2026) conducted a case report in MSI-High pulmonary artery sarcoma with Lynch syndrome (n=1). Immune checkpoint inhibitors (ipilimumab plus nivolumab, followed by pembrolizumab) was evaluated on Durable disease control and survival. Biomarker-driven immune checkpoint inhibition achieved sustained disease stability for over 65 months in a 44-year-old man with an MSI-high pulmonary artery sarcoma and Lynch syndrome.
Synapse has enriched 10 related papers. Consider them for comparative context: